{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:34Z","timestamp":1790393674489,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Eastern Finland (UEF) including Kuopio University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is still a fatal complication of DLBCL. For this reason, CNS prophylaxis is recommended for patients at high risk of CNS disease. However, no consensus exists on definition of high-risk patient and optimal CNS prophylaxis. Systemic high-dose methotrexate in combination with R-CHOP has been suggested as a potential prophylactic method, since methotrexate penetrates the blood-brain barrier and achieves high concentration in the CNS. In this retrospective analysis, we report treatment outcome of 95 high-risk DLBCL\/FL grade 3B patients treated with R-CHOP or its derivatives with (<jats:italic>N<\/jats:italic>\u2009=\u200957) or without (<jats:italic>N<\/jats:italic>\u2009=\u200938) CNS prophylaxis. At a median follow-up time (51\u00a0months), CNS relapses were detected in twelve patients (12.6%). Ten out of twelve (83%) of CNS events were confined to CNS system only. Median overall survival after CNS relapse was 9\u00a0months. Five-year isolated CNS relapse rates were 5% in the prophylaxis group and 26% in the group without prophylaxis. These findings suggest that high-dose methotrexate-containing prophylaxis decreases the risk of CNS failure.<\/jats:p>","DOI":"10.1007\/s00277-020-04140-0","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T19:03:46Z","timestamp":1592939026000},"page":"1823-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell\/follicular grade 3B lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Hanne","family":"Kuitunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-7422","authenticated-orcid":false,"given":"Elina","family":"Kaprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Makkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saila","family":"Kauppila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi-Maria","family":"Haapasaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milla","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Turpeenniemi-Hujanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"issue":"19","key":"4140_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011 May 12) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019\u20135032","journal-title":"Blood"},{"issue":"2","key":"4140_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA (2013 August 01) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146\u2013171","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"4140_CR3","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al (2005 June 20) Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117\u20134126","journal-title":"J Clin Oncol"},{"issue":"5","key":"4140_CR4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al (2006 May 01) CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"4","key":"4140_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002 January 24) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"1","key":"4140_CR6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009 January 01) Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol 27(1):114\u2013119","journal-title":"J Clin Oncol"},{"issue":"17","key":"4140_CR7","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009 April 23) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113(17):3896\u20133902","journal-title":"Blood"},{"issue":"1","key":"4140_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","volume":"15","author":"P Feugier","year":"2004","unstructured":"Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004 January 01) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15(1):129\u2013133","journal-title":"Ann Oncol"},{"key":"4140_CR9","doi-asserted-by":"crossref","unstructured":"Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 2005 August 01;19(4):609, v","DOI":"10.1016\/j.hoc.2005.05.003"},{"issue":"2","key":"4140_CR10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","volume":"105","author":"U Hegde","year":"2005","unstructured":"Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM et al (2005 January 15) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105(2):496\u2013502","journal-title":"Blood"},{"issue":"7","key":"4140_CR11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002 July 01) Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol 13(7):1099\u20131107","journal-title":"Ann Oncol"},{"issue":"4","key":"4140_CR12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","volume":"91","author":"K van Besien","year":"1998","unstructured":"van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F (1998 February 15) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178\u20131184","journal-title":"Blood"},{"issue":"5\u20136","key":"4140_CR13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/10428199909058415","volume":"32","author":"PL Zinzani","year":"1999","unstructured":"Zinzani PL, Magagnoli M, Frezza G, Prologo G, Gherlinzoni F, Bendandi M, Albertini P, Babini L, D\u2019alessandro R, Tura S (1999 February 01) Isolated central nervous system relapse in aggressive non-Hodgkin\u2019s lymphoma: the Bologna experience. Leuk Lymphoma 32(5\u20136):571\u2013576","journal-title":"Leuk Lymphoma"},{"issue":"4 Suppl 2","key":"4140_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2009.05.004","volume":"36","author":"U Herrlinger","year":"2009","unstructured":"Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F (2009 August 01) Should intracerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 36(4 Suppl 2):25","journal-title":"Semin Oncol"},{"issue":"14","key":"4140_CR15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M Shipp","year":"1993","unstructured":"Shipp M, Harrington D, Anderson J, Armitage J, Bonadonna G, Brittinger G et al (1993) A predictive model for aggressive non-Hodgkin\u2019s-lymphoma. N Engl J Med 329(14):987\u2013994","journal-title":"N Engl J Med"},{"issue":"26","key":"4140_CR16","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016 September 10) CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34(26):3150\u20133156","journal-title":"J Clin Oncol"},{"issue":"11","key":"4140_CR17","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971 November 01) Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res 31(11):1860\u20131861","journal-title":"Cancer Res"},{"issue":"1","key":"4140_CR18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004 January 01) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"4","key":"4140_CR19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999 April 01) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"5","key":"4140_CR20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007 February 10) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"2","key":"4140_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1349-7006.2011.02139.x","volume":"103","author":"N Tomita","year":"2012","unstructured":"Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K (2012 February 01) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103(2):245\u2013251","journal-title":"Cancer Sci"},{"issue":"8","key":"4140_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clml.2015.02.026","volume":"15","author":"A Ghose","year":"2015","unstructured":"Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T (2015 August 01) Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis--a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk 15(8):451\u2013457","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"4140_CR23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","volume":"21","author":"D Villa","year":"2010","unstructured":"Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010 May 01) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21(5):1046\u20131052","journal-title":"Ann Oncol"},{"issue":"1","key":"4140_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL) (2007 January 01) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149\u2013157","journal-title":"Ann Oncol"},{"issue":"5","key":"4140_CR25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J et al (2013 May 01) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 24(5):1385\u20131392","journal-title":"Ann Oncol"},{"issue":"5","key":"4140_CR26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mdr440","volume":"23","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, Haenel M, Loeffler M, Truemper L, Pfreundschuh M (2012 May 01) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23(5):1267\u20131273","journal-title":"Ann Oncol"},{"issue":"1","key":"4140_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","volume":"159","author":"HR Guirguis","year":"2012","unstructured":"Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R (2012 October 01) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 159(1):39\u201349","journal-title":"Br J Haematol"},{"issue":"5","key":"4140_CR28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","volume":"89","author":"Y Shimazu","year":"2009","unstructured":"Shimazu Y, Notohara K, Ueda Y (2009 June 01) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 89(5):577\u2013583","journal-title":"Int J Hematol"},{"issue":"11","key":"4140_CR29","doi-asserted-by":"crossref","first-page":"29442951","DOI":"10.1002\/cncr.26588","volume":"118","author":"A Kumar","year":"2012","unstructured":"Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E et al (2012 June 01) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 118(11):29442951","journal-title":"Cancer"},{"issue":"1","key":"4140_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","volume":"21","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thi\u00e9blemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, International Extranodal Lymphoma Study Group (2003 January 01) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21(1):20\u201327","journal-title":"J Clin Oncol"},{"issue":"2","key":"4140_CR31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","volume":"176","author":"R Kridel","year":"2017","unstructured":"Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, Connors JM, Savage KJ (2017 January 01) Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol 176(2):210\u2013221","journal-title":"Br J Haematol"},{"issue":"6","key":"4140_CR32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/02841869609084002","volume":"35","author":"N Keldsen","year":"1996","unstructured":"Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K (1996) Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol 35(6):703\u2013708","journal-title":"Acta Oncol"},{"issue":"11","key":"4140_CR33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","volume":"29","author":"LH Sehn","year":"2011","unstructured":"Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD (2011 April 10) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29(11):1452\u20131457","journal-title":"J Clin Oncol"},{"issue":"10","key":"4140_CR34","doi-asserted-by":"crossref","first-page":"16611669","DOI":"10.1007\/s00277-016-2744-5","volume":"95","author":"Y Kanemasa","year":"2016","unstructured":"Kanemasa Y, Shimoyama T, Sasaki Y, Tamura M, Sawada T, Omuro Y et al (2016 October 01) Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model. Ann Hematol 95(10):16611669","journal-title":"Ann Hematol"},{"issue":"8","key":"4140_CR35","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM (2011 February 24) Double-hit B-cell lymphomas. Blood 117(8):2319\u20132331","journal-title":"Blood"},{"issue":"18","key":"4140_CR36","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","volume":"127","author":"KJ Savage","year":"2016","unstructured":"Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD (2016 May 05) Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 127(18):2182\u20132188","journal-title":"Blood"},{"issue":"1","key":"4140_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","volume":"25","author":"S Li","year":"2012","unstructured":"Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ (2012 January 01) B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25(1):145\u2013156","journal-title":"Mod Pathol"},{"issue":"3","key":"4140_CR38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10428190290012092","volume":"43","author":"F Bokstein","year":"2002","unstructured":"Bokstein F, Lossos A, Lossos IS, Siegal T (2002 March 01) Central nervous system relapse of systemic non-Hodgkin\u2019s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43(3):587\u2013593","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"4140_CR39","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","volume":"111","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Herbert KE, O\u2019Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF (2014 September 09) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 111(6):1072\u20131079","journal-title":"Br J Cancer"},{"issue":"18","key":"4140_CR40","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010 September 15) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116(18):4283\u20134290","journal-title":"Cancer"},{"issue":"5","key":"4140_CR41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.13194","volume":"168","author":"AJ Ferreri","year":"2015","unstructured":"Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M et al (2015 March 01) Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168(5):654\u2013662","journal-title":"Br J Haematol"},{"issue":"7","key":"4140_CR42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","volume":"96","author":"D Villa","year":"2011","unstructured":"Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ (2011 July 01) Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 96(7):1002\u20131007","journal-title":"Haematologica"},{"issue":"2","key":"4140_CR43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A et al (2004 January 26) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90(2):353\u2013358","journal-title":"Br J Cancer"},{"issue":"6","key":"4140_CR44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","volume":"27","author":"L Brugieres","year":"2009","unstructured":"Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G et al (2009 February 20) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 27(6):897\u2013903","journal-title":"J Clin Oncol"},{"issue":"3","key":"4140_CR45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/annonc\/mdl434","volume":"18","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A (2007 March 01) The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 18(3):541\u2013545","journal-title":"Ann Oncol"},{"issue":"9","key":"4140_CR46","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1080\/1042819021000006475","volume":"43","author":"SL Chua","year":"2002","unstructured":"Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM (2002 September 01) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 43(9):1783\u20131788","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04140-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T23:36:24Z","timestamp":1624404984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04140-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4140"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04140-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective study was performed according to the Declaration of Helsinki and approved by the ethics committee of Oulu University Hospital, Finland.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}